Serum ferritin concentration in gestational diabetes mellitus and risk of subsequent development of early postpartum diabetes mellitus

Faranak Sharifi1
Amir Ziaee2
Abdolamir Feizi3
Nouraddin Mousavinasab1
Afgah Anjomshoaa1
Pooran Mokhtari4

1Zanjan Metabolic Diseases Research Center, Zanjan; 2Qazvin Metabolic Diseases Research Center, Qazvin; 3Zanjan University of Medical Sciences, Zanjan; 4Vali-e-asr Hospital, Zanjan, Iran

Purpose: To compare the serum ferritin concentrations of normal pregnant women with those having gestational diabetes mellitus (GDM) and to determine the possible role of ferritin in predicting pregnancy outcome and early development of postpartum glucose intolerance and diabetes mellitus.

Method: This case-control study consisted of 128 pregnant women (64 women with GDM and 64 age-matched healthy pregnant women) seen at a university hospital in Zanjan, Iran. Anthropometric measurements were determined, and serum ferritin, C-reactive protein, insulin, glycosylated hemoglobin (HbA1c), and hemoglobin levels were measured. Pregnancy outcomes were recorded in all subjects. In the women with GDM, a diagnostic oral glucose tolerance test was performed eight weeks after delivery.

Results: Women with GDM had a higher concentration of serum ferritin (112 ± 28.4 pmol/L in GDM versus 65 ± 16.9 pmol/L in controls, P < 0.001). A positive correlation was found between serum ferritin level and mid-pregnancy fasting plasma glucose and HbA1c levels. Although women in the highest quartile of serum ferritin had a greater than two-fold increased risk of GDM, no significant correlation was found between ferritin levels and early postpartum oral glucose tolerance test results.

Conclusions: Elevated serum ferritin concentrations in mid-pregnancy are associated with an increased risk of GDM independent of C-reactive protein and body mass index. Ferritin levels in GDM cannot be used as an indicator to predict subsequent glucose concentration in early postpartum oral glucose tolerance test.

Keywords: gestational diabetes mellitus, ferritin, pregnancy outcome, diabetes mellitus, C-reactive protein

Introduction

Recent studies have reported positive associations of serum ferritin concentrations with cardiovascular risk factors,1 risk of insulin resistance syndrome, and risk of type 2 diabetes.2–4 In our previous study in Iran, we showed elevated serum ferritin concentrations in subjects with impaired glucose tolerance, known as a prediabetic state.5

Like impaired glucose tolerance in a nonpregnant subject, gestational diabetes mellitus (GDM) is an indicator for subsequent development of diabetes mellitus (DM) after delivery.6 Women with GDM are characterized by a relatively diminished insulin secretion coupled with pregnancy-induced insulin resistance.7 Causes of insulin resistance are not completely understood; however high maternal weight is associated with
insulin resistance during pregnancy. Insulin resistance may be
due to increasing secretion of human placental lactogen and
other placental secretions or to a systemic inflammation dur-
ing pregnancy.8,9 There is an increasing recognition that iron
overload may play a role in insulin resistance at the cellular
level.10,11 Some epidemiologic studies have reported higher
levels of ferritin in women with GDM.12,13 However, data are
conflicting regarding whether elevated serum ferritin reflects
inflammation or increased iron stores.14,15 Furthermore, data
are not available on the relationship between serum ferritin
concentrations during pregnancy and insulin resistance,
and also the risk of subsequent development of postpartum
impaired glucose tolerance and overt DM. The objective of
this case-control study was to analyze serum ferritin and
C-reactive protein concentrations in GDM and also to evaluate
the association of ferritin with pregnancy outcomes and early
development of postpartum glucose intolerance and DM.

Materials and methods
This case-control study was conducted at Vali-e-asr Hospital,
a general hospital in Zanjan, a major city located to the west
of Tehran and the capital of the Iranian province with the
same name. The province has a predominantly urban popula-
tion of 1.1 million.

A total of 128 pregnant women, including 64 subjects with
GDM and 64 healthy age-matched pregnant women, were
enrolled serially at 24–28 weeks of gestation. All women with
acute or chronic inflammatory or infective diseases, history
of malignancy, DM, seizure disorders, acute or chronic
liver disease, acute or chronic renal disease, drug or alcohol
abuse, and iron deficiency anemia were excluded. Perinatal
iron supplementation was continued by all the participants
based on a national policy, and all women received an equal
dosage (50 mg of elemental iron per day) after the fourth
month of pregnancy.

Prepregnant weight was used to calculate body mass index
(BMI, weight in kilograms divided by the square of height in
meters). Blood pressure was measured with the subject seated
using a random zero sphygmomanometer. Blood pressure
was measured twice on the left upper arm, and the average
of the two measurements was used for analysis.

A two-step approach was applied to diagnose GDM. All
the women were initially screened by the glucose challenge
test with 50 g glucose at 24–28 weeks of gestation. A three-
hour oral glucose tolerance test was performed for women
with plasma glucose concentrations exceeding 130 mg/dL
on a glucose challenge test. Carpenter/Coustan diag-
nostic criteria were used to interpret oral glucose tolerance
test results.16 The fasting plasma glucose concentration of
the diagnosing oral glucose tolerance test was used as the
mid-pregnancy fasting plasma glucose in this study.

Blood samples of the participants were collected at
24–28 weeks of pregnancy after at least 12 hours of fast-
ing. Plasma glucose was measured by the glucose peroxi-
dase colorimetric enzymatic method, with a sensitivity of
5 mg/dL. Glycosylated hemoglobin (HbA1c) (normal range
4.8%–6.2%) was measured by ion exchange chromatography
with DS5. Complete blood count was performed for all the
participants using a hematologic analyzer (Sysmex, KX-21,
Toa Co, Japan). C-reactive protein was measured by a high-
sensitivity assay, with the use of the latex particle-enhanced
immunoturbidimetric assay, with an analytical sensitivity
of 0.175 mg/dL and an upper limit of normal of 5 mg/dL.
Serum ferritin was measured by a [125I] coated-tube immu-
noradiometric assay (Kavoshyar Co, Tehran). The assay
was performed in duplicate. The interassay coefficients of
variation ranged from 2% to 4%. Electrochemiluminescence
immunoassay was used to detect serum insulin concentrations
(Elecsys kit, Roche Diagnostics, Germany). The sensitivity
of the assay was 1.3 pmol/L.

All the participants were followed until delivery, and their
pregnancy outcomes were recorded. All subjects with rupture
of membranes prior to 37 weeks’ gestation were considered to
have preterm premature rupture of membranes. Preterm labor
was defined as the presence of uterine contractions of sufficient
frequency and intensity to affect progressive effacement and
dilation of the cervix prior to term gestation (20–37 weeks). Dysto-
cia was considered in subjects with difficult parturition to the point
of needing human intervention due to large fetal size.

In women with GDM an additional two-hour oral glucose
tolerance test with 75 g of glucose was performed eight weeks
after delivery. The oral glucose tolerance test results were
interpreted based on World Health Organization criteria.

Approval was obtained from the ethics committee of
Zanjan University of Medical Sciences. All the participants
were notified about the goals of the study, and informed
consent was obtained.

Statistical analysis
Data are presented as mean ± standard deviation. Proportions
were compared using the Chi-square test. Group means were
compared using the Student’s t-test and analysis of variance
(ANOVA). The Mann-Whitney test was used for variables with-
out a normal distribution. We also used log transformation for
the variables without normal distribution, like ferritin and C-reactive
protein. The Pearson correlation statistic was used to examine
the relationship between elevated serum ferritin and BMI. An odds ratio (OR) was calculated to compare the risk of GDM in people with higher ferritin levels. The conditional logistic regression analyses were performed to determine the influence of elevated serum ferritin on the risk of GDM and pregnancy morbidities. For independent variables, a change of 10 mmHg in blood pressure, 1 mg/dL of C-reactive protein, 1 µIU/L of insulin, more than the 95th percentile of serum ferritin for normal pregnant women, and changes in BMI were considered in the analysis. BMI was categorized as normal, overweight, and obese in the analysis. In addition, a stepwise multiple linear regression analysis was performed, with the two-hour blood glucose after glucose load acting as the dependent variable. A significance of \( P < 0.05 \) was used for all statistical tests.

**Results**

Ferritin and risk of GDM

The baseline characteristics of participants with and without GDM are shown in Table 1. Serum ferritin concentration was significantly higher in pregnant women with GDM. Hemoglobin levels were not significantly different between the two groups. Linear relationships between serum ferritin with mid-pregnancy fasting plasma glucose (\( r = 0.241, P = 0.01 \)) and HbA\(_1c\) were observed. A negative correlation between serum ferritin and fasting serum insulin concentration was also determined (\( r = -0.332, P = 0.02 \)). There was no significant correlation between serum ferritin and C-reactive protein levels.

A ferritin concentration of 84.7 pmol/L was calculated to be the 75th percentile for healthy pregnant women. Considering this level as the cutoff point to define high ferritin levels, 26 patients (65%) in the GDM group and 14 normal subjects (21.8%) exhibited high ferritin levels (\( P = 0.02 \)). The risk of having GDM with these high levels of ferritin was calculated to be 2.3-fold higher than that for patients with lower ferritin concentrations (OR 2.3, 95% confidence interval [CI] 1.06–5.1). For women with a ferritin level above 186 pmol/L (95th percentile for healthy pregnant women),

<table>
<thead>
<tr>
<th>Variables (mean ± SD)</th>
<th>GDM subjects (n = 64)</th>
<th>Control subjects (n = 64)</th>
<th>( P ) value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age (year)</td>
<td>30 ± 4.7</td>
<td>30 ± 4.9</td>
<td>0.8</td>
</tr>
<tr>
<td>Weight (kg)</td>
<td>75 ± 8</td>
<td>67.6 ± 9.9</td>
<td>0.00</td>
</tr>
<tr>
<td>BMI (kg/m(^2))</td>
<td>30.2 ± 3.2</td>
<td>27 ± 3.9</td>
<td>0.06</td>
</tr>
<tr>
<td>Systolic BP (mmHg)</td>
<td>111.7 ± 16</td>
<td>106.7 ± 11.9</td>
<td>0.06</td>
</tr>
<tr>
<td>Diastolic BP (mmHg)</td>
<td>72.8 ± 11.4</td>
<td>67.7 ± 9.1</td>
<td>0.01</td>
</tr>
<tr>
<td>Gravidity</td>
<td>2.8 ± 1</td>
<td>2.5 ± 0.9</td>
<td>0.9</td>
</tr>
<tr>
<td>Parity</td>
<td>1.2 ± 0.6</td>
<td>1.3 ± 0.8</td>
<td>0.4</td>
</tr>
<tr>
<td>Hb (g/dL)*</td>
<td>128 ± 8</td>
<td>125 ± 5.8</td>
<td>0.9</td>
</tr>
<tr>
<td>Ferritin (pmol/L)*</td>
<td>112.3 ± 28.4</td>
<td>65 ± 16.9</td>
<td>0.001</td>
</tr>
<tr>
<td>CRP (mg/L)*</td>
<td>9.2 ± 1.7</td>
<td>7.3 ± 0.6</td>
<td>0.09</td>
</tr>
<tr>
<td>FPG (mmol/L)*</td>
<td>5.8 ± 0.18</td>
<td>4 ± 0.27</td>
<td>0.01</td>
</tr>
<tr>
<td>Insulin (pmol/L)*</td>
<td>201 ± 111</td>
<td>347 ± 166</td>
<td>0.01</td>
</tr>
</tbody>
</table>

**GDM risk factors (freq)**

- History of abortion: 9 (14.1%) vs. 4 (6.2%) \( P = 0.1 \)
- History of stillbirth: 5 (7.8%) vs. 1 (1.5%) \( P = 0.1 \)
- History of prior GDM: 5 (7.8%) vs. 0 (0%) \( P = 0.03 \)
- Family history of DM: 30 (47%) vs. 3 (4.6%) \( P = 0.001 \)

**Pregnancy morbidities (freq)**

- Pre-eclampsia and eclampsia: 4 (6.7%) vs. 0 \( P = 0.1 \)
- Hypertension: 10 (16.7%) vs. 0 \( P = 0.001 \)
- PPROM: 2 (3.1%) vs. 2 (3.1%) \( P = 0.6 \)
- Premature labor: 5 (7.8%) vs. 1 (1.5%) \( P = 0.1 \)
- Dystocia: 3 (4.6%) vs. 0 \( P = 0.2 \)
- Abortion: 1 (1.6%) vs. 0 \( P = 0.3 \)
- LGA: 13 (20.3%) vs. 0 \( P = 0.00 \)
- LBW: 0 vs. 0
- Cesarean section: 45 (70.3%) vs. 15 (23.4%) \( P = 0.00 \)

**Note:** *All the measurements were performed at 24–28 weeks of pregnancy.*

**Abbreviations:** BMI, body mass index; BP, blood pressure; Hb, hemoglobin; FPG, fasting plasma glucose; GDM, gestational diabetes mellitus; DM, diabetes mellitus; PPROM, preterm premature rupture of membrane; LGA, large for gestational age; CRP, C-reactive protein; freq, frequency; LBW, low birth weight.
the risk of having GDM was calculated to be 4.4-fold higher than the risk for those with lower concentrations of ferritin (OR 4.4, 95% CI 1.19–16.8). This risk estimation remained significantly positive but was moderately reduced after adjustment for C-reactive protein and other confounding variables like BMI, blood pressure, history of GDM, and family history of DM (OR 2.4, 95% CI 1.2–6.8).

Logistic regression analyses were performed to determine the influence of elevated serum ferritin on the risk of GDM. Potential confounding variables, including age, familial history of DM, BMI, blood pressure, C-reactive protein, and insulin concentrations were included in multivariable models. The most potent prognostic variables in this model were family history of DM and serum ferritin concentrations (Table 2).

### GDM risk factors and pregnancy complications

Table 1 compares GDM cases with normal pregnant women for the frequency of some risk factors and pregnancy complications. Obesity was more prevalent in the cases with GDM (22 subjects [39%] in the GDM group versus nine subjects [14%] in the control group, \( P = 0.002 \)). Positive family history for DM, especially paternal history of DM, was significantly more prevalent in the GDM patients (31% of paternal DM versus 8% of history of maternal DM, \( P = 0.001 \)).

<table>
<thead>
<tr>
<th>Table 2 Logistic regression analyses of ferritin and other confounding variables to predict GDM in the pregnant women</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Dependent variable</strong></td>
</tr>
<tr>
<td>------------------------</td>
</tr>
<tr>
<td><strong>Model 1</strong> GDM</td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td><strong>Model 2</strong> GDM</td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td><strong>Model 3</strong> GDM</td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
</tbody>
</table>

**Abbreviations:** GDM, gestational diabetes mellitus; DM, diabetes mellitus; BMI, body mass index; BP, blood pressure; CRP, C-reactive protein; OR, odds ratio; CI, confidence interval.

A logistic regression analysis was used to determine the influence of elevated serum ferritin on the risk of pregnancy morbidities, including pre-eclampsia, preterm premature rupture of membranes, dystocia, and premature labor. Confounding variables including age, BMI, blood pressure, fasting plasma glucose, HbA1c, C-reactive protein, and insulin concentrations were included in the model. The only significant prognostic variable in this model was mid-pregnancy fasting plasma glucose concentrations (OR 3.1, 95% CI 1.9–18).

### Ferritin and early postpartum glucose tolerance

All the GDM subjects were evaluated eight weeks after delivery. Based on a standard oral glucose tolerance test with 75 g glucose, DM and impaired glucose tolerance were diagnosed in eight (12.5%) and 15 subjects (23.4%), respectively. A comparison between GDM patients who developed impaired glucose tolerance or DM and those who presented with a normal postpartum oral glucose tolerance test in terms of general characteristics, basal laboratory data, and pregnancy complications appears in Table 3. Although a significant difference was found in mid-pregnancy blood pressure and fasting plasma glucose between the two groups, no difference was found for blood glucose levels at hours 1, 2, or 3 after oral glucose loading at the time of diagnosis of GDM. Furthermore, the frequency of pregnancy complications was similar in both groups.

Stepwise linear regression analyses were performed to determine the relationship between elevated serum ferritin and two-hour plasma glucose in the postpartum oral glucose tolerance test. The postpartum two-hour plasma glucose concentration after a standard oral glucose tolerance test was considered to be the dependent variable. Potential confounding variables, including history of prior GDM, family history of DM, BMI, blood pressure, mid-pregnancy fasting plasma glucose, plasma glucose concentration at the first, second, and third hour after 100 g oral glucose load, C-reactive protein, and insulin concentration, were included in the model. There was no significant relationship between ferritin and two-hour plasma glucose concentration in the postpartum oral glucose tolerance test. We determined that only mid-pregnancy fasting plasma glucose (OR 1.05, 95% CI 1.01–1.1) and BMI (OR 1.4, 95% CI 1.2–4.7) were prognostic for postpartum two-hour plasma glucose concentration in the oral glucose tolerance test. Although a correlation between positive family history of DM and presence of hypertension during
Table 3 Comparison of basal clinical characteristics, biochemical indices, past history, and pregnancy complications between two groups of women with GDM based on their postpartum OGTT results (n = 64)

<table>
<thead>
<tr>
<th>Variables (mean ± SD)</th>
<th>Impaired glucose tolerance or DM (n = 23)</th>
<th>Normal glucose tolerance (n = 41)</th>
<th>P</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age (years)</td>
<td>30.3 ± 1.1</td>
<td>30.4 ± 0.7</td>
<td>0.9</td>
</tr>
<tr>
<td>BMI (kg/m²)</td>
<td>31.3 ± 0.5</td>
<td>29.6 ± 0.5</td>
<td>0.06</td>
</tr>
<tr>
<td>Systolic BP (mmHg)</td>
<td>118 ± 40</td>
<td>107.7 ± 21</td>
<td>0.01</td>
</tr>
<tr>
<td>Diastolic BP (mmHg)</td>
<td>77 ± 25</td>
<td>70 ± 17</td>
<td>0.03</td>
</tr>
<tr>
<td>Hb (g/dL)</td>
<td>129 ± 2.3</td>
<td>128 ± 1.8</td>
<td>0.8</td>
</tr>
<tr>
<td>Ferritin (pmol/L)</td>
<td>107.8 ± 22</td>
<td>115.9 ± 24.7</td>
<td>0.8</td>
</tr>
<tr>
<td>CRP (mg/L)</td>
<td>9.5 ± 1.5</td>
<td>8.9 ± 1.9</td>
<td>0.09</td>
</tr>
<tr>
<td>FPG (mmol/L)</td>
<td>6.1 ± 0.2</td>
<td>5 ± 0.17</td>
<td>0.00</td>
</tr>
<tr>
<td>Insulin (pmol/L)</td>
<td>234 ± 122</td>
<td>182 ± 99</td>
<td>0.06</td>
</tr>
<tr>
<td>1-hour BS in GTT (mmol/L)</td>
<td>10.8 ± 0.76</td>
<td>9.6 ± 0.3</td>
<td>0.08</td>
</tr>
<tr>
<td>2-hour BS in GTT (mmol/L)</td>
<td>10.8 ± 0.85</td>
<td>9.8 ± 0.58</td>
<td>0.3</td>
</tr>
<tr>
<td>3-hour BS in GTT (mmol/L)</td>
<td>9.4 ± 1.2</td>
<td>7.8 ± 0.3</td>
<td>0.3</td>
</tr>
<tr>
<td>HbA1c (%)</td>
<td>5.16 ± 0.19</td>
<td>5.1 ± 0.16</td>
<td>0.8</td>
</tr>
</tbody>
</table>

GDM risk factors (freq)

<table>
<thead>
<tr>
<th>Variables</th>
<th>Impaired glucose tolerance or DM (n = 23)</th>
<th>Normal glucose tolerance (n = 41)</th>
<th>P</th>
</tr>
</thead>
<tbody>
<tr>
<td>History of abortion</td>
<td>4 (17.3)</td>
<td>5 (12)</td>
<td>0.9</td>
</tr>
<tr>
<td>History of stillbirth</td>
<td>2 (8.7)</td>
<td>3 (7.3)</td>
<td>0.6</td>
</tr>
<tr>
<td>History of prior GDM</td>
<td>4 (17.3)</td>
<td>1 (2.4)</td>
<td>0.06</td>
</tr>
<tr>
<td>Family history of DM</td>
<td>16 (69.5)</td>
<td>14 (34)</td>
<td>0.08</td>
</tr>
</tbody>
</table>

Pregnancy morbidity (freq)

<table>
<thead>
<tr>
<th>Variables</th>
<th>Impaired glucose tolerance or DM (n = 23)</th>
<th>Normal glucose tolerance (n = 41)</th>
<th>P</th>
</tr>
</thead>
<tbody>
<tr>
<td>Pre-eclampsia and eclampsia</td>
<td>4 (17.3)</td>
<td>0</td>
<td>0.06</td>
</tr>
<tr>
<td>Hypertension</td>
<td>4 (17.3)</td>
<td>2 (4.8)</td>
<td>0.1</td>
</tr>
<tr>
<td>PPROM</td>
<td>1 (4.3)</td>
<td>1 (2.4)</td>
<td>0.6</td>
</tr>
<tr>
<td>Premature labor</td>
<td>3 (13)</td>
<td>2 (4.8)</td>
<td>0.2</td>
</tr>
<tr>
<td>Dystocia</td>
<td>3 (13)</td>
<td>0</td>
<td>0.052</td>
</tr>
<tr>
<td>LGA</td>
<td>8 (34.7)</td>
<td>6 (14.6)</td>
<td>0.04</td>
</tr>
<tr>
<td>Cesarean section</td>
<td>18 (78.3)</td>
<td>27 (65.9)</td>
<td>0.2</td>
</tr>
</tbody>
</table>

Abbreviations: BMI, body mass index; BP, blood pressure; Hb, hemoglobin; FPG, fasting plasma glucose; CRP, C-reactive protein; 1-hour BS, blood sugar one hour post-OgTT in mid-pregnancy; 2-hour BS, blood sugar two hours post-OgTT; 3-hour BS, blood sugar three hours post-OgTT; OGTT, oral glucose tolerance test; GDM, gestational diabetes mellitus; DM, diabetes mellitus; PPROM, preterm premature rupture of membrane; LGA, large for gestational age.

Discussion

We found a significant association between serum ferritin levels and GDM that was independent of BMI and C-reactive protein. However, no association of serum ferritin levels with pregnancy morbidities or postpartum glucose concentration in the oral glucose tolerance test was found.

Other studies have revealed that higher ferritin levels raise the risk of DM and prediabetic conditions. Whether this association is independent of BMI is not clear. Few data regarding the correlation of ferritin levels and body fat during pregnancy have been reported. In spite of reports from China that revealed no correlation between ferritin levels and BMI in pregnant Chinese women, a report from the US demonstrated a significant correlation. In the current study, ferritin level was an independent prognostic factor for GDM and was highly correlated with glycemic control.

Women with GDM are characterized by relatively diminished insulin secretion, coupled with pregnancy-induced insulin resistance, primarily in skeletal muscle tissue. In the current study, it is interesting that the fasting serum insulin concentration was significantly lower in the GDM group than in the non-GDM group (201 ± 111 versus 347 ± 166 pmol/L). Although a lower insulin level was not an independent risk factor for developing GDM in this study, this finding implies that insulin secretion might be decreased in the GDM group. There have been similar reports stating that β-cell function is decreased in patients with GDM.

It is not clear how ferritin is related to insulin deficiency or to insulin resistance. Ferritin has been identified as a marker of inflammation, and pregnancy is considered an inflammatory state. Whether or not elevated serum ferritin in GDM is a consequence of inflammation is not clear. Although it would be of interest to assess levels of ferritin at different time points of pregnancy, we could not do that because of difficult accessing the same subjects on several occasions. However,
with the case-control design used in our study, the effect of the inflammatory state of pregnancy on ferritin levels has been removed. Similar to a previous study, we did not find a positive correlation between C-reactive protein (an inflammation marker) and ferritin. On the other hand, although the role of ferritin as a potent indicator of GDM was confirmed in this study, C-reactive protein was not able to be determined to be an independent risk factor for development of GDM.

Jiang et al. found that high serum ferritin and C-reactive protein levels are independent risk factors for type 2 diabetes. These data are inconsistent with the role of inflammation in raising ferritin levels in GDM and other insulin-resistant states.

Ferritin can reflect body iron stores. Higher iron stores can be associated with insulin resistance in nonpregnant subjects. Lao et al. found that higher hemoglobin (\(>13\) g/dL) was an independent risk for GDM and that iron deficiency anemia is associated with a lower risk of GDM. Like a previous report, our results revealed no correlation between ferritin and hemoglobin concentrations. Furthermore, no difference in hemoglobin concentrations was found between women with GDM and the control group. Although these findings do not support the hypothesis that higher serum ferritin levels reflect excess iron stores in patients with GDM, we cannot rule out subclinical manifestations of iron overload in GDM. One limitation of our study is that we did not measure serum iron or serum transferrin concentrations, which would have helped us to interpret the role of serum ferritin as a marker of iron overload during pregnancy. Minimal iron excess that does not have a significant effect on the hemoglobin concentration may affect insulin action or insulin secretion at the cellular level. Recently, a genetic susceptibility to iron overload in GDM was suggested.

GDM was a potent risk factor for subsequent development of DM, increasing the risk of DM by 12.5%. Mid-pregnancy fasting plasma glucose (and not postoral glucose tolerance test blood sugars) and BMI were the strongest prognostic factors for early postpartum impaired glucose tolerance or DM. Ferritin was not correlated with blood glucose levels after delivery. Lack of a correlation between ferritin and postpartum glucose tolerance test results may be due to the relatively small sample size. On the other hand, an oral glucose tolerance test was performed eight weeks after delivery, which may have been too early to find an association between ferritin level and glucose intolerance. Furthermore, a family history of DM and history of prior GDM were proven not to be independent predictors of postpartum DM. Although these data are consistent with those reported by Huidobro, there are reports of high postpartum oral glucose tolerance test plasma glucose levels that predict future DM. We could not find any study on ferritin as a risk factor for postpartum diabetes. This is the first report in this field that demonstrates the lack of any relationship between ferritin levels at the time of diagnosis of GDM and early postpartum oral glucose tolerance test results.

In conclusion, we found that the serum ferritin level is highly associated with GDM independently of BMI and C-reactive protein, the mid-pregnancy ferritin level is not a prognostic factor for pregnancy morbidity or subsequent impaired glucose tolerance after delivery, and fasting plasma glucose values at the time of diagnosis of GDM are the most important prognostic factors for glucose concentration in an early postpartum oral glucose tolerance test.

Acknowledgments

This study was supported by the Zanjan University of Medical Sciences. We are grateful to Dr Sheikholeslami, Dr Najimi, and the laboratory staff of the primary health care units in Zanjan for their assistance in this research.

Disclosure

All authors disclose no relevant conflicts of interest in this work.

References